• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Transcranial Direct Current Stimulation
Clinical Update

Transcranial Direct Current Stimulation

August 1, 2024
Kelvin Quiñones-Laracuente, MD, PhD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Kelvin Quiñones-Laracuente, MD, PhD. Psychiatry resident, NYU Langone Medical Center.

Dr. Quiñones-Laracuente has no financial relationships with companies related to this material.

Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation device that uses a low-intensity current to stimulate specific areas of the brain. Although popular for depression and other conditions, it is not cleared by the FDA. A growing community of students, professionals, and hobbyists, as well as people with mental health conditions, are using tDCS devices at home. They may be using tDCS to enhance their cognitive abilities or to alleviate certain physical or mental health conditions. Many purchase commercially available tDCS devices online ($100–$500) or build their own using kits ($20–$150).

Is tDCS effective?

While tDCS for depression treatment is backed by controlled trials, its evidence base isn’t as solid as that of established therapies, and its effect size is fairly small (0.3). This effect size was determined from a meta-analysis of 11 tDCS studies focused on depression that used sham devices as controls (Meron D et al, Neurosci Biobehav Rev 2015;57:46–52).

Nearly all the studies reviewed suffered from small sample sizes (less than 100 participants) and showed mixed results. One of the larger, more statistically robust studies divided 120 participants with major depressive disorder into four groups: tDCS with placebo, tDCS with the antidepressant sertraline, and their respective sham counterparts. Notably, 20% of the participants had treatment-resistant depression. The results showed that combining sertraline with tDCS led to a 12-point reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) score compared to placebo, while tDCS alone decreased the MADRS score by 6 points. This highlights the enhanced effectiveness of combination therapy (Brunoni A et al, JAMA Psychiatry 2013;70(4):383–391), as reported in the April 2013 TCPR.

tDCS also holds promise for treating other conditions, such as generalized anxiety disorder and attention deficit hyperactivity disorder, but the data supporting these uses are limited and based on smaller trials.

Is tDCS safe?

The FDA has not cleared tDCS for any indication, so it is always prescribed off-label. It is not without risk (Oh J et al, Clin Psychopharmacol Neurosci 2022;20(1):87–96). Patients may lack the knowledge or training necessary to use the device safely and effectively, and there is a risk that the user will push the voltage beyond the studied range. This can cause skin irritation on the stimulation areas, neck pain, headaches, and tingling sensations.

Additionally, any unmonitored psychiatric treatment carries safety concerns. Depression affects judgment in ways that interfere with insight and treatment planning, leading to delays in recovery or—in the worst case—suicide.

Mechanism of action

Like transcranial magnetic stimulation (TMS), tDCS operates via electromagnetic fields to evoke neural activity. However, the two methods differ in their intensity and the nature of their ­stimulation.

TMS applies robust magnetic pulses that are capable of inducing action potentials, the swift alterations in transmembrane neuronal voltage that transmit information. On the other hand, tDCS uses a substantially weaker current, between 0.5 and 2 milliamperes, that doesn’t prompt action potentials. Rather, it can subtly modify the voltage within neurons. For a point of reference, ECT administers approximately 800 milliamperes per impulse, a significantly higher amount.

Researchers still don’t fully understand the underlying mechanisms of tDCS, but the technique may influence the activity of neurotransmitters such as serotonin and dopamine. Enhanced neuronal signaling has been noted when tDCS is combined with substances like citalopram or levodopa (Nitsche M et al, Biol Psychiatry 2009;66(5):503–508; Kuo M et al, Cereb Cortex 2008; 18(3):648–651).

Additionally, evidence from animal models suggests that tDCS might boost neuroplasticity, a vital process for learning and memory. This observation was derived from experiments where tDCS was paired with thalamic stimulation (Fritsch B et al, Neuron 2010;66(2):198–204).

Clinical practice insights

Can tDCS response predict TMS response? We have no head-to-head studies of the two methods, but we do know that their mechanisms differ as described earlier. We also know that other forms of electromagnetic stimulation therapy, like ECT, are effective as an adjunctive treatment for depression. Serotonergic and dopaminergic agents also appear to synergize with tDCS, which makes it favorable when supplementing ongoing ­pharmacotherapy.

If your patient decides to pursue tDCS, have them track their symptoms with a rating scale like the Patient Health Questionnaire (PHQ-9) before and after tDCS.

Dosing depends on three parameters: current, duration, and location. The current is between 1 and 2 milliamperes. The duration is 20 minutes daily for five to 15 days. Most studies place the anode patch over the left dorsolateral and ventromedial cortex (known as F3 in EEG placement) and the cathode patch over the right supraorbital area of the forehead (F4 in EEG placement). These locations can be identified with three head measurements: head circumference, distance from nasion to inion (nose to back of the head), and distance from tragus to tragus (ear to ear). You can find software that helps pinpoint this area at www.clinicalresearcher.org/software.htm (Beam W et al, Brain Stim 2010;2(1):50–54). Finally, for a primer on how to implement tDCS, see www.tinyurl.com/4zceu4k

CARLAT VERDICT 

tDCS involves passing direct current across the brain. It is weaker than TMS, but it has some benefits for depression. It is not recommended for treatment-resistant depression. 

General Psychiatry Clinical Update
KEYWORDS depression neuromodulation neuropsychiatry
    Kelvin Quiñones-Laracuente, MD, PhD

    Stimulant Dosing Limits for ADHD: When Is The Adderall / Ritalin Dose Too High?

    More from this author
    www.thecarlatreport.com
    Issue Date: August 1, 2024
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Suicide, TCPR, August 2024
    Novel Treatment Options for OCD
    Suicide Assessment and Treatment
    Transcranial Direct Current Stimulation
    Antipsychotic Dosing: Differences Between Bipolar Mania and Schizophrenia
    Listen to The Carlat Psychiatry Report, August 2024, Volume 22, Issue 8, “Suicide”
    CME Post-Test, Suicide, TCPR, August 2024
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.